Drug Profile
V 404
Alternative Names: V404; V404 PDS; V404 port delivery systemLatest Information Update: 16 Jan 2017
Price :
$50
*
At a glance
- Originator ForSight VISION4
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Uveitis
Most Recent Events
- 10 Jan 2017 ForSight VISION4 has been acquired by and merged into Roche
- 19 Aug 2016 No recent reports on development identified - Phase-I/II for Uveitis in USA (Intraocular)
- 04 Mar 2015 ForSight VISION4 terminates phase I/II clinical trial in Uveitis in USA (NCT02125266)